Logo image of MDWD

MEDIWOUND LTD (MDWD) Stock Fundamental Analysis

NASDAQ:MDWD - Nasdaq - IL0011316309 - Common Stock - Currency: USD

19.5  +0.35 (+1.83%)

Premarket: 18.6 -0.9 (-4.62%)

Fundamental Rating

2

Taking everything into account, MDWD scores 2 out of 10 in our fundamental rating. MDWD was compared to 195 industry peers in the Pharmaceuticals industry. MDWD has a bad profitability rating. Also its financial health evaluation is rather negative. MDWD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MDWD had negative earnings in the past year.
In the past year MDWD has reported a negative cash flow from operations.
In the past 5 years MDWD reported 4 times negative net income.
MDWD had negative operating cash flow in 4 of the past 5 years.
MDWD Yearly Net Income VS EBIT VS OCF VS FCFMDWD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M

1.2 Ratios

MDWD has a Return On Assets of -37.55%. This is comparable to the rest of the industry: MDWD outperforms 45.70% of its industry peers.
With a Return On Equity value of -81.96%, MDWD perfoms like the industry average, outperforming 45.16% of the companies in the same industry.
Industry RankSector Rank
ROA -37.55%
ROE -81.96%
ROIC N/A
ROA(3y)-39.31%
ROA(5y)-27.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDWD Yearly ROA, ROE, ROICMDWD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 -200

1.3 Margins

The Gross Margin of MDWD (12.42%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of MDWD has declined.
The Profit Margin and Operating Margin are not available for MDWD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.98%
GM growth 5Y-13.05%
MDWD Yearly Profit, Operating, Gross MarginsMDWD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

MDWD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDWD has more shares outstanding
MDWD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MDWD is higher compared to a year ago.
MDWD Yearly Shares OutstandingMDWD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
MDWD Yearly Total Debt VS Total AssetsMDWD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

MDWD has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
MDWD's Debt to Equity ratio of 0.19 is in line compared to the rest of the industry. MDWD outperforms 43.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC9.01%
MDWD Yearly LT Debt VS Equity VS FCFMDWD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M 30M

2.3 Liquidity

MDWD has a Current Ratio of 2.11. This indicates that MDWD is financially healthy and has no problem in meeting its short term obligations.
MDWD's Current ratio of 2.11 is in line compared to the rest of the industry. MDWD outperforms 40.86% of its industry peers.
A Quick Ratio of 1.99 indicates that MDWD should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.99, MDWD perfoms like the industry average, outperforming 44.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 1.99
MDWD Yearly Current Assets VS Current LiabilitesMDWD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for MDWD have decreased strongly by -64.77% in the last year.
MDWD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.03%.
MDWD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.61% yearly.
EPS 1Y (TTM)-64.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-308.33%
Revenue 1Y (TTM)-21.03%
Revenue growth 3Y-4.95%
Revenue growth 5Y40.61%
Sales Q2Q%-8.81%

3.2 Future

The Earnings Per Share is expected to grow by 26.55% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 40.68% on average over the next years. This is a very strong growth
EPS Next Y-343.77%
EPS Next 2Y-75.05%
EPS Next 3Y-28.59%
EPS Next 5Y26.55%
Revenue Next Year8.13%
Revenue Next 2Y16.55%
Revenue Next 3Y19.16%
Revenue Next 5Y40.68%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MDWD Yearly Revenue VS EstimatesMDWD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
MDWD Yearly EPS VS EstimatesMDWD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDWD. In the last year negative earnings were reported.
Also next year MDWD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDWD Price Earnings VS Forward Price EarningsMDWD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDWD Per share dataMDWD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as MDWD's earnings are expected to decrease with -28.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-75.05%
EPS Next 3Y-28.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDWD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIWOUND LTD

NASDAQ:MDWD (2/4/2025, 8:00:00 PM)

Premarket: 18.6 -0.9 (-4.62%)

19.5

+0.35 (+1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-26 2024-11-26/bmo
Earnings (Next)N/A N/A
Inst Owners38.48%
Inst Owner Change0.41%
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap210.41M
Analysts84
Price Target29.58 (51.69%)
Short Float %10.23%
Short Ratio12.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-87.72%
Min EPS beat(2)-116.72%
Max EPS beat(2)-58.73%
EPS beat(4)1
Avg EPS beat(4)-77.62%
Min EPS beat(4)-153.13%
Max EPS beat(4)18.12%
EPS beat(8)3
Avg EPS beat(8)-34.6%
EPS beat(12)4
Avg EPS beat(12)-27.75%
EPS beat(16)7
Avg EPS beat(16)-21.02%
Revenue beat(2)0
Avg Revenue beat(2)-15.4%
Min Revenue beat(2)-28.91%
Max Revenue beat(2)-1.9%
Revenue beat(4)1
Avg Revenue beat(4)-7.07%
Min Revenue beat(4)-28.91%
Max Revenue beat(4)4.26%
Revenue beat(8)3
Avg Revenue beat(8)3.42%
Revenue beat(12)5
Avg Revenue beat(12)2.98%
Revenue beat(16)9
Avg Revenue beat(16)4.63%
PT rev (1m)0%
PT rev (3m)-2.52%
EPS NQ rev (1m)-15.76%
EPS NQ rev (3m)-6.11%
EPS NY rev (1m)-2.66%
EPS NY rev (3m)-25.47%
Revenue NQ rev (1m)-18.9%
Revenue NQ rev (3m)-25.36%
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)-15.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.67
P/FCF N/A
P/OCF N/A
P/B 6.15
P/tB 6.17
EV/EBITDA N/A
EPS(TTM)-2.9
EYN/A
EPS(NY)-2.36
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS1.83
BVpS3.17
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.55%
ROE -81.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.42%
FCFM N/A
ROA(3y)-39.31%
ROA(5y)-27.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.98%
GM growth 5Y-13.05%
F-Score2
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 536.81%
Cap/Sales 38.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.11
Quick Ratio 1.99
Altman-Z N/A
F-Score2
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)193.23%
Cap/Depr(5y)146.56%
Cap/Sales(3y)12.92%
Cap/Sales(5y)9.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-308.33%
EPS Next Y-343.77%
EPS Next 2Y-75.05%
EPS Next 3Y-28.59%
EPS Next 5Y26.55%
Revenue 1Y (TTM)-21.03%
Revenue growth 3Y-4.95%
Revenue growth 5Y40.61%
Sales Q2Q%-8.81%
Revenue Next Year8.13%
Revenue Next 2Y16.55%
Revenue Next 3Y19.16%
Revenue Next 5Y40.68%
EBIT growth 1Y-85.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.47%
OCF growth 3YN/A
OCF growth 5YN/A